MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has announced a significant development in mental health treatment for adolescents. Health Care Service Corporation (HCSC) has expanded coverage for transcranial magnetic stimulation (TMS) therapy to include adolescents aged 15 and older diagnosed with major depressive disorder (MDD). This update aligns with the recent FDA clearance for NeuroStar TMS Therapy as a first-line add-on treatment for this age group.
HCSC, the largest customer-owned health insurer in the U.S., now extends TMS coverage to teenagers without the requirement of prior medication failure. This policy update, effective October 1, 2024, impacts over 15 million lives across several states, including Illinois and Texas.
Keith J. Sullivan, President and CEO of Neuronetics, Inc., remarked, “This milestone policy by HCSC is a testament to the growing recognition that our young people need earlier access to proven mental health treatments like NeuroStar TMS. We commend HCSC for their leadership in patient access.”
This move reflects a broader trend among insurers to enhance mental health treatment access, reinforcing Neuronetics’ role as a pioneer in TMS therapy for adolescents.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.